Holen Sie sich die Stockscreener-App
20.34
3.56%
0.70
Handel nachbörslich:
20.34
Schlusskurs vom Vortag:
$19.64
Offen:
$19.31
24-Stunden-Volumen:
565.53K
Relative Volume:
0.57
Marktkapitalisierung:
$1.31B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-221.04M
KGV:
-5.4761
EPS:
-3.7143
Netto-Cashflow:
$-178.65M
1W Leistung:
+14.72%
1M Leistung:
+14.46%
6M Leistung:
+75.50%
1J Leistung:
+168.34%
1-Tages-Spanne:
$18.58
$20.37
1-Wochen-Bereich:
$17.30
$21.00
52-Wochen-Spanne:
$5.68
$21.00
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Firmenname
Cullinan Therapeutics Inc
Sektor
Branche
Telefon
617-410-4650
Adresse
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
20.34 | 1.26B | 0 | -221.04M | -178.65M | -3.7143 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-17 | Eingeleitet | Citigroup | Buy |
| 2026-02-02 | Eingeleitet | Guggenheim | Buy |
| 2025-08-21 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-06-11 | Fortgesetzt | Stifel | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-05-01 | Eingeleitet | Stifel | Buy |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-06-15 | Eingeleitet | TD Cowen | Outperform |
| 2022-11-21 | Eingeleitet | BTIG Research | Buy |
| 2021-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Eingeleitet | Evercore ISI | Outperform |
| 2021-02-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Assenagon Asset Management S.A. Sells 77,023 Shares of Cullinan Therapeutics, Inc. $CGEM - marketbeat.com
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 30,000 Shares - marketbeat.com
Cullinan Therapeutics (CGEM) investor group discloses 6,491,123-share position - Stock Titan
Cullinan Therapeutics, Inc.Common Stock (CGEM) Stock Price, News, Quote & History - FinancialContent
Cullinan Therapeutics (CGEM): T. Rowe Price reports 6.2% ownership stake - Stock Titan
CGEM (CGEM) insider to sell 30,000 shares after stock option exercise - Stock Titan
Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Op - Benzinga
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up After Analyst Upgrade - marketbeat.com
CGEM Maintains Outperform Rating -- Price Target Raised to $42.0 - GuruFocus
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $42.00 - marketbeat.com
Cullinan Therapeutics (CGEM) Shares Rise 6% Premarket on Positive Lung Cancer Trial Results - GuruFocus
New Taiho, Cullinan data heats up lung cancer drug battle - Yahoo Finance
Show Me The Money: Did You Miss CGEM's Rally? Here's What Comes Next - RTTNews
Cullinan rises on trial win for lung cancer drug (CGEM:NASDAQ) - Seeking Alpha
Cullinan: REZILIENT3 Phase 3 Interim Shows Improved PFS for Zipalertinib + Chemo - TradingView
Cullinan Therapeutics, Inc. $CGEM Shares Bought by The Manufacturers Life Insurance Company - marketbeat.com
Cullinan Therapeutics Says Phase 3 Trial of Experimental Lung Cancer Drug Met Primary Endpoint - Yahoo Finance
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - marketbeat.com
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. Report Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 Rezilient3 Trial in First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer - marketscreener.com
Zipalertinib trial meets primary endpoint in lung cancer study - Investing.com Nigeria
Zipalertinib trial meets primary endpoint in lung cancer study By Investing.com - Investing.com Australia
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer - marketscreener.com
HC Wainwright Issues Pessimistic Outlook for CGEM Earnings - marketbeat.com
Biotech Stocks At 52-Week HighsALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH - RTTNews
Cullinan Oncology stock hits 52-week high at 19.43 USD By Investing.com - Investing.com UK
Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 52-Week HighStill a Buy? - marketbeat.com
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Cullinan Oncology stock hits 52-week high at 19.43 USD - Investing.com
Cullinan Therapeutics (CGEM) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
Dimensional Fund Advisors LP Has $12.87 Million Stock Position in Cullinan Therapeutics, Inc. $CGEM - marketbeat.com
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cullinan Therapeutics (NASDAQ:CGEM) Issues Quarterly Earnings Results - MarketBeat
Cullinan Therapeutics Inc (CGEM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cullinan Therapeutics (CGEM): State Street discloses 3.67M-share, 6% ownership stake - Stock Titan
The Bull Case For Cullinan Therapeutics (CGEM) Could Change Following FDA-Backed Phase 2 CLN-049 Trial - Yahoo Finance
Renaissance Technologies LLC Sells 307,595 Shares of Cullinan Therapeutics, Inc. $CGEM - MarketBeat
JonesTrading Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Cullinan Therapeutics, Inc. Stock 12‑Month Price Target Raised to $33, Implies 87% Upside - TradingView
Cullinan Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Cullinan Therapeutics Q2 net loss narrows - TradingView
Cullinan Therapeutics 3Q 2026: Revenue $0 Net loss $53.7M, EPS $(0.81) — 10-Q Summary - TradingView
Cullinan Therapeutics: Q2 Earnings Snapshot - barchart.com
CGEM: Pipeline advances and strong cash position support growth and late-stage clinical milestones - TradingView
Cullinan Therapeutics reports Q2 2026 net loss of $53.7M, cash and investments $356.0M - TradingView
BRIEF-Cullinan Therapeutics Q2 Operating Income USD -57.254 Million Vs. IBES Estimate USD -57.1 Million - TradingView
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - GlobeNewswire
Cullinan Oncology earnings up next: Can pipeline justify cash burn? By Investing.com - Investing.com UK
CGEM|Cullinan Therapeutics Inc|Price:16.260|Chg%:-0.240 - tradingkey.com
Cullinan Therapeutics (CGEM) Slides 5.8% as Pipeline-Focused Biotech Faces Key Support Test at $15.67Unusual Put Volume - dars.gov.et
Cullinan Therapeutics (NASDAQ:CGEM) Lowered to Sell Rating by Wall Street Zen - marketbeat.com
Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):